Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > L2... Huge numbers on the Bid site
View:
Post by whisky11 on Apr 19, 2021 9:27am

L2... Huge numbers on the Bid site

Level II Quotes
Orders
Shares
Bid
Ask
Shares
Orders
17
275,000
0.055
0.055
810,000
16
28
2,311,000
0.05
0.06
1,321,000
23
27
5,379,000
0.045
0.065
1,129,000
13
19
2,699,000
0.04
0.07
1,447,000
15
7
1,248,000
0.035
0.075
1,338,000
24
Comment by Moonshiner592 on Apr 19, 2021 9:29am
That's what we want!! 
Comment by bud13 on Apr 19, 2021 9:50am
looks like someone's selling er down. 1.2m now and.045 bids
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities